Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.
The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.
Gilead CMO quits six months after taking job; Allergan taps Pfizer vet as CMO; and Novartis recruits Siemens ethics chief as it reels from scandal.
The imminent departure leaves Pfenex without a CMO as it gears up to file a new drug application (NDA), although Chen will continue to advise the biotech.
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Males of soybean cyst nematode, or H. glycines, are able reverse neurodegeneration as part of their natural life cycle.
Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.
Evecxia has officially named John Kaiser as its CEO and interim chairman of its board of directors, after working with the Duke spinout since March.
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
In this week's EuroBiotech Report, Pfizer, BioNTech ink $425 million deal, British biotechs reel in $247 million in VC cash and more.